Syncom Formulations (India) Limited

Equities

SYNCOMF

INE312C01025

Pharmaceuticals

Market Closed - Bombay S.E. 11:49:01 2024-04-29 pm EDT 5-day change 1st Jan Change
13.98 INR +0.94% Intraday chart for Syncom Formulations (India) Limited +0.65% -7.18%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Syncom Formulations Limited Announces Board Changes CI
Syncom Formulations Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Syncom Formulations Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Syncom Formulations Begins Commercial Production at Expanded Plant in Pithampur, India MT
Syncom Formulations Limited Commences Commercial Production CI
Syncom Formulations Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Syncom Formulations Limited Announces Commercial Production Starts from 30 June 2023 CI
Syncom Formulations Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Syncom Formulations Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Syncom Formulations Limited Announces Executive Changes CI
Syncom Formulations Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Syncom Formulations Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Syncom Formulations Limited Approves the Declaration of Dividend for the Financial Year Ended 31 March 2022 CI
Syncom Formulations Sees Delay in Completion of Expansion Project MT
Syncom Formulations Limited Announces Updates on its Project for Expansion Cum Modernisation of Existing Plant at Pithampur CI
Syncom Formulations Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Syncom Formulations Limited Appoints Ruchi Jindal as an Additional Director CI
Syncom Formulations Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Syncom Formulations Limited Announces Executive Changes CI
Syncom Formulations Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021 CI
Syncom Formulations India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021 CI
Syncom Formulations Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020 CI
Syncom Formulations Limited announced that it has received INR 100.787496 million in funding CI
Syncom Formulations Limited Announces Expansion of Existing Plant at Pithampur CI
Syncom Formulations Limited announced that it expects to receive INR 100.787496 million in funding CI
Chart Syncom Formulations (India) Limited
More charts
Syncom Formulations (India) Limited is an India-based company that is engaged in the pharmaceutical business. The Company is engaged in the manufacturing and dealing in pharmaceutical drugs and formulations, and trading of commodities. It is also engaged in the renting of properties. It manufactures and markets a range of pharmaceutical formulations in various dosage forms, such as tablets, capsules, liquids orals, liquid vials and ampoule injections and dry powder injections, ophthalmic preparations, dry syrups and suspensions, ointments, creams, gel, ORS and jelly. The Company's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Cefuroxime For Injection USP 750 mg and Gentamicin Injection BP 40 mg.
More about the company
  1. Stock Market
  2. Equities
  3. SYNCOMF Stock
  4. News Syncom Formulations (India) Limited
  5. Syncom Formulations Begins Commercial Production at Expanded Plant in Pithampur, India